GLP-1 pills are coming, and they could revolutionize weight-loss treatment
At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...
MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions
Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...
Becker's Hospital Review16d
GLP-1 weight loss pills are in the works: What to know
GLP-1 weight loss medications like Ozempic and Wegovy have become blockbuster drugs, but the need for weekly injections has limited their use. This may soon change, as several oral versions are ...
Next frontier in anti-obesity landscape: oral GLP-1s with potential OTC switch
Viking Therapeutics (VKTX) leads the race to win FDA Rx-to-OTC switch for an oral weight loss drug belonging to GLP-1 class ...
BioPharma Dive11d
The golden era of GLP-1 drugs: Where we are and what comes next
Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) are entero-pancreatic hormone-based treatments first approved in 2005 for type 2 diabetes (T2D). They are now commonly prescribed for weight ...
MedCity News25d
Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study
An experimental GLP-1 obesity drug from Terns Pharmaceuticals led to a 5.5% reduction in body weight in a small study, continuing to build its case as a potential oral alternative to currently ...
MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment
MangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss ...
Viking Therapeutics: Market Excited By GLP-1 Promise -- A Buy Ahead Of Oral Data
Viking Therapeutics, Inc.'s stock surged 1,500% on the promising obesity drug VK-2735, with Phase 3 trials and potential for ...